Breast Cancer Clinical Trial
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
Summary
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid in patients with breast cancer metastatic to bone.
The study will also evaluate the possible effects of both study drugs on performance status, markers of bone metabolism, and skeletal events related to bone metastasis including elevated blood calcium levels, bone pain, metastatic lesions, complications and interventions. The levels of CAL in the blood will also be evaluated.
Eligibility Criteria
Major Inclusion Criteria - Others Stipulated within the Protocol
The study physician must assure you have/are:
Must be a female at least 18 years of age and be using an effective form of birth control.
A documented history of breast cancer and at least one bone metastasis that has not been previously treated by radiation or surgery, and is not anticipated to be treated within the next 24 weeks.
A total body bone scan and other radiographic scan(s) performed on you within 4 weeks prior to or during the screening period sufficient to image all sites of bone metastases.
You must be willing to perform a daily telephone diary and be willing to keep a paper diary and provide voluntary consent to participate in this study.
Major Exclusion Criteria - Others Stipulated within the Protocol
The study physician must assure you do not have/are not:
A change in analgesic (pain relief) type medication during the screening period (example, non-narcotic to narcotic).
Received radiation therapy to any bone metastasis or started a new course of chemotherapy within 3 weeks prior to the screening visit or during the screening period.
Used any bisphosphonate type drug during the 30 days prior to the anticipated first dose of study drug
Vertebral spine or weight-bearing bone metastasis that would place you at imminent risk for fracture or surgical intervention.
Evidence of active infection or immune deficiency, renal failure, abnormal liver function, or a serum calcium level > 10.1 mg/dL.
Use of any investigational drug within 30 days prior to screening.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 35 Locations for this study
Little Rock Arkansas, 72205, United States
Springdale Arkansas, 72764, United States
Concord California, 94520, United States
Greenbrae California, 94904, United States
Los Angeles California, , United States
Vista California, 92083, United States
Aurora Colorado, 80010, United States
New Haven Connecticut, 06520, United States
Ft. Lauderdale Florida, 33308, United States
Chicago Illinois, 60612, United States
Lexington Kentucky, 40536, United States
New Orleans Louisiana, 70112, United States
Frederick Maryland, 21701, United States
Boston Massachusetts, 02115, United States
Detroit Michigan, 48202, United States
Grand Rapids Michigan, 49503, United States
Southfield Michigan, 48076, United States
St. Louis Missouri, 63128, United States
Las Vegas Nevada, 89109, United States
Lebanon New Hampshire, 03756, United States
Santa Fe New Mexico, 87505, United States
Bronx New York, 10467, United States
Brooklyn New York, 11235, United States
New York New York, 10021, United States
Syracuse New York, 12310, United States
Durham North Carolina, 27710, United States
Cleveland Ohio, 44106, United States
Cleveland Ohio, 44106, United States
Columbus Ohio, 43235, United States
Hershey Pennsylvania, 17033, United States
Columbia South Carolina, 29203, United States
Memphis Tennessee, 38104, United States
Memphis Tennessee, 38104, United States
Memphis Tennessee, 38120, United States
Corpus Christi Texas, 78412, United States
Dallas Texas, 75230, United States
Houston Texas, 77030, United States
Milwaukee Wisconsin, 53226, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.